Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accomplish, acoustic, administered, adult, alongside, analogy, Anchor, Arabia, Argentina, Asian, assumption, augment, begun, belief, BioCardia, Biotech, bland, Blue, bond, Breakthrough, BSC, budget, carboxypeptidase, carcinoma, catastrophic, Center, Cerene, Chile, Chinese, cholangiopancreatography, Colombia, Columbia, complementary, condensed, confirmed, congressional, consequential, CroFab, cryotherapy, curve, cybersecurity, Czech, database, deadline, Decompression, Dialogue, DigiFab, digoxin, DIRECTSENSE, divided, dose, duodenoscope, Eastern, electrode, empower, empowering, ERCP, escalate, escalation, EXALT, excretion, Fab, factually, Fenner, Fountain, GDPR, globe, GMP, guideline, HCC, Hemoclip, hepatocellular, HMO, IM, ImageReady, Immune, implicit, indemnify, Indonesia, Inflation, Inline, Instinct, inventorship, IPR, Janssen, Jonathan, kit, Korean, land, Linkbase, literature, Los, Louisiana, LSS, lumbar, Lynch, MDD, median, Merrill, methotrexate, micromole, microsphere, misleading, Mississippi, Monson, Municipal, necessarily, North, Nova, obsolescence, occurrence, online, oral, OrionTM, outreach, overdose, overexposure, Ovine, pancreaticobiliary, physical, physiology, Pierce, pit, plasma, POLARx, presidential, prevalence, Prosthetic, proud, proven, QSF, quantity, radioactive, Red, renal, renminbi, Republic, residual, Retail, retention, retrograde, RPI, SAB, Saudi, Schema, Scotia, scrap, secret, Securityholder, Shave, Sherman, Shield, Slovakia, slower, Smith, Solyx, space, specialist, specialty, stability, Superion, supersede, Taiwan, Taxonomy, testimony, Thailand, Therasphere, tool, toxic, toxicity, Turkey, UDAAN, unaudited, uncapped, underrepresented, undisclosed, unfunded, unremitted, Valley, Varian, Vertiflex, Vietnam, viper, vital, volunteered, Voraxaze, warehouse, weaker, Wear, withdrew, won, worker, XBRL, zytiga
Removed:
aforementioned, Alpharetta, apportionment, aware, brand, bringing, capable, cell, circumstance, clarification, comparability, conducting, consultant, decided, deficiency, disclosing, distributor, doctrine, Dr, EEA, endochoice, enforced, expended, factor, finalized, flat, Georgia, Greece, hdx, inactive, ineffective, intervention, Jang, jury, Lesh, literal, literally, lost, Maria, Markman, nonprofit, Orion, oversee, pathology, payor, Portugal, Quincy, remanded, reorganization, rescission, responding, rolled, scrutinizing, SpA, Spain, stipulation, today, unreduced, updating, vacated, warfarin, wholly
Filing tables
Filing exhibits
- 10-K Annual report
- 4.2 Exhibit 4.2 - Description of Registered Securities FY2019
- 21 Exhibit 21 - FY2019 List of Subsidiaries Dated Jan 30, 2020
- 23 Exhibit 23 - E&y Consent FY2019
- 31.1 Exhibit 31.1 CEO 302 Cert FY2019
- 31.2 Exhibit 31.2 CFO 302 Cert FY2019
- 32.1 Exhibit 32.1 CEO 906 Cert FY2019
- 32.2 Exhibit 32.2 CFO 906 Cert FY2019
- Download Excel data file
- View Excel data file
Related press release
Associated BSX transcripts
BSX similar filings
Filing view
External links
EXHIBIT 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Boston Scientific Corporation (the “Company”) for the period ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:
(1) | the Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and | |
(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation. |
By: | /s/ Daniel J. Brennan | |
Daniel J. Brennan | ||
Executive Vice President and Chief Financial Officer | ||
February 25, 2020 |